Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

Ying G. Li(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Christopher D. Payne(Eli Lilly (United States)), Nagy A. Farid(Eli Lilly (United States)), Lan Ni(Eli Lilly (United States)), Shashank Rohatagi(Daiichi Sankyo (United States)), John T. Brandt(Universitätsklinikum Würzburg), Joseph A. Jakubowski(Indiana Biosciences Research Institute), C. Steven Ernest(Metrum Research Group (United States)), David S. Small(Eli Lilly (United States))
Platelets
January 1, 2009
10.1080/09537100903046317
Cited by 61

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
|American Heart Journal|2006|571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537